Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inupadenant
EOS100850 · 3 trials · 3 indications
Incidence of dose-limiting toxicities
Incidence of adverse events (AEs), serious adverse events, AEs leading to discontinuation, deaths, and clinically significant laboratory abnormalities.
Time from first dose to the date of first documented radiologic progression per RECIST v1.1 or time of death, whichever comes first
Incidence of adverse events (AEs), serious adverse events (SAEs), DLTs, AEs leading to discontinuation, deaths, electrocardiogram (ECG) abnormalities, and clinically significant laboratory abnormalities
To assess safety and tolerability as measured by incidence and severity of AEs
To define the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of EOS100850 in patients receiving EOS100850
To assess safety and tolerability as measured by incidence and severity of AEs
| Arm | Type | Description |
|---|---|---|
| Part 1, open label | EXPERIMENTAL | Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D). |
| Part 2, active treatment | EXPERIMENTAL | Treatment with inupadenant combined with carboplatin and pemetrexed |
| Part 2, placebo | PLACEBO_COMPARATOR | Treatment with matched placebo combined with carboplatin and pemetrexed |
| Inupadenant sequential dose escalation (Part 1A) | EXPERIMENTAL | Part 1A will evaluate the safety as well as to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of inupadenant in participants with advanced solid tumors. |
| Inupadenant randomized crossover (Part 1B) | EXPERIMENTAL | The effect of food on the exposure to inupadenant will be investigated in participants with advanced solid tumors. |
| Inupadenant single treatment assignment (Part 1C) | EXPERIMENTAL | Part 1C will investigate an additional formulation of inupadenant in participants with advanced solid tumors. |
| 1A Dose escalation EOS100850 | EXPERIMENTAL | Dose Escalation- EOS100850 Monotherapy: to confirm RP2D |
| 1B Dose escalation EOS100850 and Pembrolizumab | EXPERIMENTAL | EOS100850 and Pembrolizumab Combination Therapy: to confirm RP2D as combination |
| 2A Dose Expansion- EOS100850 | EXPERIMENTAL | Dose Expansion - EOS100850 Monotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant as monotherapy |
| 2B Dose Expansion - EOS100850 and Pembrolizumab | EXPERIMENTAL | Dose Expansion - EOS100850 and Pembrolizumab Combination Therapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with pembrolizumab in melanoma and CRPC patients |
| 2D Dose expansion - EOS100850 and Chemotherapy in TNBC | EXPERIMENTAL | Dose expansion - EOS100850 and Chemotherapy Combination: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC |
| 3 EOS100850 in BMK-H participants | EXPERIMENTAL | Dose expansion - EOS100850 Monotherapy : to evaluate the safety, PD, and antitumor activity of inupadenant as monotherapy at the mono-RP2D in BMK-H participants in 4 disease-specific cohorts: NSCLC; HNSCC; EC; and other forms of cancer |
| Name | Type | Description |
|---|---|---|
| inupadenant | DRUG | Adenosine 2a receptor antagonist |
| Placebo | DRUG | matched placebo capsule to inupadenant |
| Carboplatin | DRUG | standard of care chemotherapeutic, alkylating agent |
| Pemetrexed | DRUG | standard of care chemotherapeutic, anti-metabolite |
| EOS100850 | DRUG | Oral administration |
| Pembrolizumab | DRUG | IV Infusion |
| Chemotherapy | DRUG | Standard of Care IV Infusion |
Inclusion Criteria: * Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology * Measurable disease as defined by RECIST v1.1 * PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible...
EOS100850 is an investigational small molecule being studied for the treatment of adult patients with solid tumors. It is being developed as a potential cancer therapy and is not approved for any indication. The clinical program has focused on patients with advanced solid tumors in oncology settings.
EOS100850 targets the A2A receptor, a receptor class target. By binding to the A2A receptor, the drug is designed to modulate adenosine signaling in the tumor microenvironment. This mechanism is being explored as a way to support antitumor immune activity in patients with solid tumors.
EOS100850 is being developed by iTeos Therapeutics, Inc., which trades under the ticker ITOS. The company is the sponsor of the clinical program evaluating this small molecule in adult patients with solid tumors.
EOS100850 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program has been completed, with no active trials currently listed.
EOS100850 has been evaluated in one clinical trial, NCT03873883, titled First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer. This completed Phase 1 trial enrolled 119 adult patients with solid tumors across the United States, Belgium, France, South Korea, Spain, and the United Kingdom.
Yes, EOS100850 is also known as inupadenant. The two names refer to the same investigational small molecule developed by iTeos Therapeutics. The first-in-human trial is titled with both names, confirming they are used interchangeably for this A2A receptor targeting agent.